NOVOPROTEIN SCIENTIFIC INC. — Investor Relations & Filings
About NOVOPROTEIN SCIENTIFIC INC.
Novoprotein Scientific Inc. specializes in the development and manufacture of high-quality recombinant proteins and enzymes for life sciences and biopharmaceutical applications. The company provides a comprehensive portfolio of products, including cytokines, growth factors, viral antigens, and diagnostic enzymes, which are utilized in research, drug discovery, and the development of cell and gene therapies. Novoprotein offers specialized services such as custom protein expression and purification across various platforms, including mammalian, insect, and microbial systems. By leveraging advanced protein engineering and large-scale production technologies, the company supports global research institutions and commercial partners in advancing medical diagnostics and therapeutic innovation. Its focus remains on delivering bioactive reagents that meet rigorous quality standards for consistency and performance.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2025年度独立董事述职报告(金坚) | 2026-04-28 | Chinese | |
| 容诚会计师事务所关于近岸蛋白募集资金存放与使用的专项审核报告 | 2026-04-28 | Chinese | |
| 容诚会计师事务所关于近岸蛋白2025年度营业收入扣除情况的专项审核报告 | 2026-04-28 | Chinese | |
| 董事会审计委员会对2025年度审计会计师履行监督职责情况报告 | 2026-04-28 | Chinese | |
| 容诚会计师事务所关于近岸蛋白内部控制审计报告 | 2026-04-28 | Chinese | |
| 2025年非经营性资金占用及其他关联资金往来情况专项说明 | 2026-04-28 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39561015 | 2025年度独立董事述职报告(金坚) | 2026-04-28 | Chinese | ||
| 39561009 | 容诚会计师事务所关于近岸蛋白募集资金存放与使用的专项审核报告 | 2026-04-28 | Chinese | ||
| 39560889 | 容诚会计师事务所关于近岸蛋白2025年度营业收入扣除情况的专项审核报告 | 2026-04-28 | Chinese | ||
| 39560762 | 董事会审计委员会对2025年度审计会计师履行监督职责情况报告 | 2026-04-28 | Chinese | ||
| 39560759 | 容诚会计师事务所关于近岸蛋白内部控制审计报告 | 2026-04-28 | Chinese | ||
| 39560691 | 2025年非经营性资金占用及其他关联资金往来情况专项说明 | 2026-04-28 | Chinese | ||
| 39560664 | 2025年度独立董事述职报告(张宗新) | 2026-04-28 | Chinese | ||
| 39560630 | 2025年度“提质增效重回报”行动方案年度评估报告暨2026年度“提质增效重回报”行动方案 | 2026-04-28 | Chinese | ||
| 39560623 | 2025年度利润分配预案的公告 | 2026-04-28 | Chinese | ||
| 39560622 | 2025年度董事会审计委员会履职情况报告 | 2026-04-28 | Chinese | ||
| 39560612 | 2025年年度报告摘要 | 2026-04-28 | Chinese | ||
| 39560611 | 2025年度会计师事务所履职情况评估报告 | 2026-04-28 | Chinese | ||
| 39560606 | 董事、高级管理人员薪酬管理办法 | 2026-04-28 | Chinese | ||
| 39560602 | 关于2025年度计提资产减值准备的公告 | 2026-04-28 | Chinese | ||
| 39560595 | 2026年第一次临时股东会会议资料 | 2026-04-26 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
NOVOPROTEIN SCIENTIFIC INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58178/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58178 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58178 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58178 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58178}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NOVOPROTEIN SCIENTIFIC INC. (id: 58178)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.